Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: Results of the prospective PREDICT trial

Haematologica

Volumn 98, Issue 2, 2013, Pages 172-178

  Russell, Nigel ^a   Douglas, Kenny ^b   Ho, Anthony D ^c   Mohty, Mohamad ^d   Carlson, Kristina ^e   Ossenkoppele, G J ^f   Milone, Giuseppe ^g   Pareja, Macarena Ortiz ^h   Shaheen, Daniel ⁱ   Willemsen, Arnold ^j   Whitaker, Nicky ^k   Chabannon, Christian ^l  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d NANTES UNIVERSITY HOSPITAL   (France)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF CATANIA   (Italy)

^h not available   (Spain)

ⁱ Sanofi Oncology   (United States)

^j Genzyme Europe BV   (Netherlands)

^k Genzyme SAS ^*  (France)

^l INSTITUT PAOLI CALMETTES   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; PLERIXAFOR; HETEROCYCLIC COMPOUND;

ABDOMINAL PAIN; ADULT; AGED; APHERESIS; ARTICLE; CLINICAL TRIAL; DEATH; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GRAFT FAILURE; HEART INFARCTION; HEMATOPOIETIC STEM CELL; HUMAN; HYPOMAGNESEMIA; INJECTION SITE REACTION; LEUKOCYTOSIS; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; OPEN STUDY; PERIPHERAL BLOOD STEM CELL; PROSPECTIVE STUDY; RECURRENT DISEASE; SIDE EFFECT; STEM CELL MOBILIZATION; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; DRUG EFFECTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LYMPHOMA, NON-HODGKIN; MIDDLE AGED;

ADULT; AGED; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HETEROCYCLIC COMPOUNDS; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MULTIPLE MYELOMA; TREATMENT OUTCOME;

EID: 84875351754     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.071456     Document Type: Article

References (16)

1. Gazitt Y, Freytes CO, Callander N, Tsai TW, Alsina M, Anderson J, et al. Successful PBSC mobilization with high-dose G-CSF for patients failing a first round of mobilization. J Hematother. 1999;8(2):173-83.
2. Porrata LF, Gertz MA, Inwards DJ, Litzow MR, Lacy MQ, Tefferi A, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood. 2001; 98(3):579-85.
3. Lazarus HM, Loberiza FR, Jr., Zhang MJ, Armitage JO, Ballen KK, Bashey A, et al. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplant. 2001;27(4):387-96.
4. Sureda A, Arranz R, Iriondo A, Carreras E, Lahuerta JJ, Garcia-Conde J, et al. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J Clin Oncol. 2001;19(5):1395-404.
5. Allan DS, Keeney M, Howson-Jan K, Popma J, Weir K, Bhatia M, et al. Number of viable CD34(+) cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;29(12):967-72.
6. Wuchter P, Ran D, Bruckner T, Schmitt T, Witzens-Harig M, Neben K, et al. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant. 2010;16(4):490-9.
7. Giralt S, Stadtmauer E, Harousseau J, Palumbo A, Bensinger W, Comenzo R, et al. International Myeloma Working Group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia. 2009; 23(10):1904-12.
8. van Der Auwera P, Platzer E, Xu ZX, Schulz R, Feugeas O, Capdeville R, et al. Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (Ro 25-8315) in healthy volunteers: comparison with single and multiple daily doses of filgrastim. Am J Hematol. 2001;66(4):245-51.
9. Cassens U, Momkvist PH, Zuehlsdorf M, Mohr M, Kienast J, Berdel WE, et al. Kinetics of standardized large volume leukapheresis (LVL) in patients do not show a recruitment phenomenon of peripheral blood progenitor cells (PBPC). Bone Marrow Transplant. 2001;28(1):13-20.
10. Pusic I, Jiang S, Landua S, Uy G, Rettig M, Cashen A, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant. 2008;14(9):1045-56.
11. Pusic I, DiPersio J. The use of growth factors in hematopoietic stem cell transplantation. Current Pharmaceutical Design. 2008;14(20):1950-61.
12. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol. 2009;27(28):4767-73.
13. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, et al. Plerixafor and G-CSF versus placebo and GCSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113(23):5720-6.
14. Mozobil [Summary of Product Characteristics], Naarden, Netherlands: Genzyme Europe B.V.: 2010.
15. Neupogen [Prescribing Information]. Thousand Oaks, CA: Amgen Inc.: 2012.
16. Tricot G, Jagannath S, Vesole D, Nelson J, Tindle S, Miller L, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood. 1995;85(2):588-96.